Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.54 |
| ▸ | CMA1 | P23946 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alacepril SCHEMBL11460465 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL5058556 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL20126832 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL683027 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL34559 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL28035498 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL677447 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL11458085 | 0.95 | ACE (0.51) | ACESLC6A2ACE2CMA1OPRM1 | |
| SCHEMBL11282561 | 0.93 | SLC6A2 (0.56) | ACESLC6A2CMA1OPRM1 | |
| SCHEMBL683119 | 0.93 | SLC6A2 (0.56) | ACESLC6A2CMA1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11222439-A | — | — | None | — | — | JP | disclosed |
| EP-2198869-B1 | TREHALOSE FOR THE TREATMENT OR PREVENTION OF VASOSPASM | NEXT 21 K K (JP) | 2015-09-16 | — | — | EP | disclosed |
| US-8283337-B2 | Therapeutic or prophylactic agent for vasoconstriction | NEXT21 K.K. (JP) | 2012-10-09 | — | — | US | disclosed |
| EP-2198869-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR VASOCONSTRICTION | Next 21 K.K. (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-20100035837-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR VASOCONSTRICTION | NEXT21 K.K. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1323434-B1 | Method for diagnostic imaging of the renal region using a contrast agent and a vasodilator | IMARX PHARMACEUTICAL CORP (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1323434-A2 | Improved methods for diagnostic imaging using a contrast agent and a vasodilator | IMARX PHARMACEUTICAL CORP. (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-0977597-B1 | IMPROVED METHODS FOR DIAGNOSTIC IMAGING USING A CONTRAST AGENT AND A VASODILATOR | IMARX PHARMACEUTICAL CORP (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6071494-A | LIPID, PROTEIN OR POLYMER AND A GAS OR GASEOUS PRECURSOR, IN COMBINATION WITH A RENAL VASODILATOR. | IMARX PHARMACEUTICAL CORP. (US) | 2000-06-06 | — | — | US | disclosed |
| JP-H11222439-A | INHIBITOR OF CEREBRAL VASOSPASM | DAINIPPON PHARMACEUT CO LTD | 1999-08-17 | — | — | JP | disclosed |